Logotipo del repositorio
 

Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety

Vista sencilla de ítem
dc.contributor.authorTéllez Arévalo, Angélica María
dc.contributor.authorQuaye, Abraham
dc.contributor.authorRojas-Rodríguez, Luis Carlos
dc.contributor.authorPoole, Brian D.
dc.contributor.authorBaracaldo-Santamaría, Daniela
dc.contributor.authorTellez Freitas, Claudia M.
dc.contributor.corporatenamePontificia Universidad Javeriana. Facultad de Medicina. Departamento de Ciencias Fisiológicasspa
dc.contributor.javerianateacherTéllez Arévalo, Angélica María
dc.date.accessioned2023-03-14T14:17:03Z
dc.date.available2023-03-14T14:17:03Z
dc.date.created2022-12-27
dc.description.abstractenglishThe pharmacological treatment of systemic lupus erythematosus (SLE) aims to decrease disease activity, progression, systemic compromise, and mortality. Among the pharmacological alternatives, there are chemically synthesized drugs whose efficacy has been evaluated, but which have the potential to generate adverse events that may compromise adherence and response to treatment. Therapy selection and monitoring will depend on patient characteristics and the safety profile of each drug. The aim of this review is to provide a comprehensive understanding of the most important synthetic drugs used in the treatment of SLE, including the current treatment options (mycophenolate mofetil, azathioprine, and cyclophosphamide), review their mechanism of action, efficacy, safety, and, most importantly, provide monitoring parameters that should be considered while the patient is receiving the pharmacotherapy.spa
dc.description.esciNospa
dc.description.indexingRevista Internacional - Indexadaspa
dc.description.orcidhttps://orcid.org/0000-0002-8468-8716spa
dc.description.publindexA2spa
dc.description.quartilescopusQ2spa
dc.description.quartilewosQ3spa
dc.formatPDFspa
dc.format.mimetypeapplication/pdfspa
dc.identifierhttps://www.mdpi.com/1648-9144/59/1/56spa
dc.identifier.doihttps://doi.org/10.3390/medicina59010056spa
dc.identifier.instnameinstname:Pontificia Universidad Javerianaspa
dc.identifier.issn1010-660X / 1648-9144 (Electrónico)spa
dc.identifier.reponamereponame:Repositorio Institucional - Pontificia Universidad Javerianaspa
dc.identifier.repourlrepourl:https://repository.javeriana.edu.cospa
dc.identifier.urihttp://hdl.handle.net/10554/63756
dc.language.isoengspa
dc.relation.citationendpage47spa
dc.relation.citationissue1spa
dc.relation.citationstartpage1spa
dc.relation.citationvolume59spa
dc.relation.ispartofjournalMedicina-Lithuaniaspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.licenceAtribución-NoComercial 4.0 Internacional*
dc.source.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subject.keywordImmunosuppressant agentspa
dc.subject.keywordGlucocorticoidspa
dc.subject.keywordAntimalarial drugspa
dc.subject.keywordEfficacyspa
dc.subject.keywordSafetyspa
dc.subject.keywordSystemic lupus erythematosusspa
dc.titleSynthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safetyspa
dc.type.coarhttp://purl.org/coar/resource_type/c_dcae04bcspa
dc.type.hasversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.localArtículo de revistaspa

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Synthetic Pharmacotherapy for Systemic Lupus Erythematosus Potential Mechanisms of Action, Efficacy, and Safety.pdf
Tamaño:
1.69 MB
Formato:
Adobe Portable Document Format
Descripción:
Artículo
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
2.54 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos